Please assess the completion status of the following clinical trial:

Trial Title: Varenicline For Nicotine Vaping Cessation In Non Smoker Vaper Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18-25 inclusive;~* Self report of daily or near daily nicotine vaping for the prior ≥ 3 months, screening semi-quantitative urine cotinine positive for recent nicotine use, exhaled CO \<10 ppm and score ≥4 on the 10-item E-cigarette Dependence Inventory (ECDI);~* Self-report of no combusted tobacco use in the past 2 months at enrollment;~* Total body weight at screening ≥35 kg (77 lbs) and Body Mass Index (BMI) ≤35 kg/m2;~* Report motivation to quit vaping in the next 30 days;~* Able to understand study procedures and read and write in English;~* Competent and willing to consent to participate in study procedures.~Exclusion Criteria:~* Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion);~* Unwillingness to abstain during the study from using smoking cessation aids other than those provided by the study;~* Unstable medical condition, epilepsy, severe renal impairment;~* Evidence of active problem substance use severe enough in the investigator's opinion to compromise ability to safely participate;~* Prior adverse drug reaction to varenicline;~* Unwilling to provide urine samples;~* Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: EXPERIMENTAL): Participants will receive varenicline 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive identical placebo 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
- Monitoring only (Type: NO_INTERVENTION): Participants will attend weekly and monthly sessions that will only consist of assessments. No study medication, no behavioral or texting support.

Based on this trial design, predict the completion outcome and termination type (if applicable).